Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Amneal Pharmaceuticals, Inc.

A Comparative Analysis of SG&A Expenses: Pfizer Inc. vs. Amneal Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Pfizer Inc. and Amneal Pharmaceuticals, Inc., from 2014 to 2023.

Pfizer, a global leader, consistently reported SG&A expenses averaging around $14 billion annually, showcasing a stable yet significant investment in operational costs. In contrast, Amneal Pharmaceuticals, a relatively smaller player, demonstrated a growth trajectory in SG&A expenses, increasing by over 400% from 2014 to 2023. This rise reflects Amneal's strategic expansion efforts and market penetration.

Understanding these financial dynamics offers insights into each company's strategic priorities and operational scale, providing a window into their competitive strategies in a rapidly changing market landscape.